Compliance to Live Oral Ty21a Typhoid Vaccine, and its Effect on Viability
|
|
- Dorothy Green
- 5 years ago
- Views:
Transcription
1 Compliance to Live Oral Ty21a Typhoid Vaccine, and its Effect on Viability Claire-Lise Fallab Stubi, Pierre R. Landry, Christine Pétignat, Jacques Bille, Blaise Genton, Roger Darioli, and Michel Burnier Background: Concerns have been expressed that in travelers the efficacy of the live oral Ty21a typhoid vaccine Vivotif could be lower than reported, maybe due to a lack of compliance. The purpose of this study was to examine the level of compliance with the recommendations regarding dosing, timing of dosing with respect to food intake, and storage. Method:Travelers were randomized into two groups: one received oral information only, and the second, a combination of oral and written information. Four criteria of compliance were applied to travelers: 3 capsules needed to be swallowed (criterion 1) on day 1, 3 and 5 (criterion 2), at least 1 hour before or 2 hours after a meal (criterion 3) and the vaccine had to be kept refrigerated (2 8 C) (criterion 4). Compliance was evaluated using three different methods: a questionnaire, pill counting, and electronic monitoring using the Medication Event Monitoring System (MEMS ). Storage conditions were checked by temperature tags, and viability of the vaccine was assessed by culturing the content of remaining capsules. Results:The data of 115 travelers were analyzed. All the travelers took the 3 capsules. Compliance to all four criteria was complete in 68% of travelers according to the questionnaire, and 53% according to the MEMS (p =.05). Sixty-seven percent of all the doses intervals were of 48 hours 6 hours, 12% being shorter than 36 hours and 7% longer than 60 hours. Eighty-seven travelers (76%) took their capsules on each alternate day. The method of information had no significant impact on compliance. Forty-two percent of tags showed exposure to temperature over 10 C for more than 24 hours. Yet, no difference could be found in the viability of the vaccine compared with controls. Conclusions: Most travelers take their 3 capsules on alternate days, but many did not follow the other recommendations. Electronic monitoring of compliance provides more accurate results than questionnaires. Emphasis must be put on motivating the travelers to take the vaccine as recommended. Typhoid fever is a serious febrile disease due to a gram-negative enterobacterium, Salmonella typhi, acquired by ingestion of contaminated food or water. Typhoid fever is endemic in developing countries but most cases in Europe and in the United States are imported. Between 1989 and 1997,20 to 50 cases have been reported annually in Switzerland, 1,2 and most of the cases got infected abroad, mainly in Asia. The global risk for travelers has been estimated at 1: 30,000, but higher incidences have Claire-Lise Fallab Stubi, Pierre R. Landry, MD, DTMH, Blaise Genton, MD, PhD, Roger Darioli, and MD, Michel Burnier, MD: University Medical Policlinic, Lausanne, Switzerland; Christine Pétignat, MD, and Jacques Bille, Professor: Institute of Microbiology, University Hospital, Lausanne, Switzerland. These results were presented orally at the Fourth International Conference on Travel Medicine, April 23 27, 1995, Acapulco, Mexico. The vaccines used in this study and partial financial support were given by Berna (Vivotif ), Bern, Switzerland. Reprint requests: C-L. Fallab Stubi, Policlinique Médicale Universitaire, Rue César Roux 19, 1005 Lausanne, Switzerland. J Travel Med 2000; 7: been reported in high risk groups or in high risk destinations. 3 Therefore an efficient and well tolerated vaccine would be welcomed to complete the prophylactic measures recommended to travelers at risk. Two vaccines have been developed in the last decade, an injectable polysaccharide capsular vaccine made of Vi antigen from S. typhi (Typhim-Vi,Pasteur Merieux) showing a protective efficacy of 75 to 81%, 4,5 and a live attenuated oral vaccine made of a mutated Salmonella typhi (Ty21a strain) (Vivotif, Berna) showing a protective efficacy of 50 to 96%. 6 9 In Switzerland, this last vaccine is given orally in three doses, as one gastroresistant capsule every other day, and should be kept between 2 and 8 Celsius. Protection under constant exposure lasts 3 years, but only 1 year in nonendemic conditions. All the studies of efficacy have been conducted in populations of endemic areas,but not in travelers. 6 9 There has been concern that the efficacy in travelers could be much lower than reported. 10 Causes incriminated have been a lack of antigenicity, whether by absence of natural exposure to the bacteria or by a too low content in S. typhi,or non observance of the recommendations for use Indeed, following the multiple recommendations for taking the vaccine requires a high level of compliance, and compliance is known to be poor when instructions for use are complicated or numerous. 13 All the studies of 133
2 134 Journal of Travel Medicine, Volume 7, Number 3 compliance in the use of Vivotif Berna vaccine have been done by questionnaires with results showing that dosing at the appropriate interval, and refrigeration issues, to be the most common compliance errors. 11,14,15 Assessing compliance by this method is limited by the subjectivity of the participants. In general, self reporting questionnaires asking the patient about his own compliance overestimate true compliance. 16 New methods of compliance assessment include electronic monitoring, 17,18 which takes off the subjectivity linked to questionnaire assessment by precisely timing the openings of the vial containing the drug or vaccine under evaluation. Comparisons between electronic monitoring of drug compliance, and pill count or urine tests, have repeatedly demonstrated that both the pill count and the urine tests overestimate drug compliance Thus,electronic monitoring is considered today, the most reliable approach to monitor compliance to drug therapy. It has been used extensively to monitor or sustain adherence to drug regimen in several diseases including epilepsy, tuberculosis, and hypertension. 20,22,23 This study aimed at measuring compliance of travelers in taking the oral typhoid vaccine Vivotif as recommended after oral, or oral plus written explanations, with the use of an electronic monitoring device, with the pill count, and with a questionnaire. The impact of nonobservance of the requirements for storage on the viability of S. typhi contained in the vaccine was assessed as well. Subjects and Methods Vaccine and Recommendations for Use The Vivotif vaccine,produced by Berna,Switzerland, contains 10 9 units of attenuated Salmonella typhi (Ty21a strain) per capsule. To ensure an effective vaccination four criteria must be fulfilled: 3 capsules need to be swallowed (criterion 1) on day 1, 3 and 5 (criterion 2), at least 1 hour before or 2 hours after a meal (criterion 3), and the vaccine must be kept refrigerated (2 8 C) (criterion 4). Subjects All successive willing travelers over 18-years-old visiting our travel clinic prior to a trip to high risk areas were asked to participate. High risk areas at the time of the study included Nepal, India, Peru, Egypt, Morocco, Algeria or Libya, or any developing country when the planned trip was longer than a month in standard conditions, or longer than 10 days in poor conditions of hygiene. Breast-feeding or pregnant women, travelers on antibiotics or immunocompromised subjects were excluded. All travelers received clear information on the study and gave informed consent. The protocol was approved by the local ethical committee. A preliminary questionnaire recorded personal data, data on the planned journey, the health of the travelers, and on concomitant drugs being taken. On the same day as they entered the study,the travelers received other necessary vaccines and recommendations on malaria prophylactics, as well as preventive measures against diarrhea. Intervention Travelers were allocated into two groups by simple random procedure (pre-prepared envelop): one group received oral information about the use of the vaccine, and the other received oral and written information (a card provided by the manufacturers). All travelers received a questionnaire asking about date and time of meals, time of use of medication, side effects, place of storage, and a MEMS (Medication Event Monitoring System, APREX Corporation, Palo Alto, CA) consisting of a bottle, closed with a cap containing a microprocessor recording the date and the time of all openings. This system assumes that each bottle opening corresponds to a dose taken. They were made aware of the MEMS recording process and the bottle was filled with 6 capsules of vaccine and 2 time/temperature tags (Monitor Mark 3M), one recording any temperature over 10 C, and the other one any temperature over 30 C. The travelers had to take the bottle home, keep it in their refrigerator, take the capsules of vaccine as recommended, fill in the questionnaire, and bring the bottle with the tags and the remaining capsules back as soon as possible after taking the last dose. Compliance Assessment Three methods were used to monitor compliance: a questionnaire, the pill count, and the MEMS. Compliance was evaluated based on the four criteria described under the vaccine description. The travelers with bottles opened more than three times, with an opening-time series corresponding to a schedule of alternate days, and a matching questionnaire were considered compliant. Viability Assessment A sample of the remaining capsules in the bottles, both from travelers who had kept them under 10 as recommended, and from those who had not, were sent for culture to the Microbiology Laboratory of the University Hospital of Lausanne. The contents were cultivated on gelose blood, TSA (tryptic soy agar), and MacConkey media, and determination of the number of bacteria (CFUs) was performed after dilution. A set of capsules of the same lot used in the study, was kept under strict observation of temperature conditions, and tested before and after the study, to serve as control.
3 Stubi et al., Compliance to Oral Ty21a Vaccine 135 Statistical Analysis The analysis used standard t-tests and chi-squared tests whenever appropriate. Results are presented as median values. Results From a total of 120 travelers enrolled, 5 were excluded from compliance analysis (4 due to MEMS technical failure, and 1 who didn t return the questionnaire). The median age of the 115 travelers included was 32 years (range 19 72); there were 62 males and 53 females. Sixty (52.2 %) subjects were assigned to the oral information group and 55 (47.8 %) to the oral plus written information group. The gender, age and reason for traveling were similar in both groups. Ninety percent of them received malaria recommendations as well as the vaccine. Minor side effects were reported by 41/115 travelers (35.7%), usually gastrointestinal (n = 25), less frequently systemic (n = 16). The side effects were similar among females and males (n = 24/53 and 17/62 respectively, p =.005) and were less frequent after the second and third capsule. No difference in incidence of side effects was found between the 92% of travelers who had received other vaccines than the oral typhoid on the same day and those who had not (32/93 vs. 11/22, p = n.s) even for the systemic effects (14/93, vs. 2/22, p = n.s). Compliance in Taking the Capsules The compliance according to the three different methods of evaluation is summarized in Table 1. Nearly all travelers took three capsules. Compared to the MEMS, the questionnaire evaluation overestimated compliance in taking the three capsules on alternate days (p =.01), and in keeping an interval with the meals as recommended. Compliance to all 4 criteria was complete in only 68% of travelers according to the questionnaire, and 53% according to the MEMS (p =.05). Figure 1 shows the distribution of the intervals between 2 doses, according to the MEMS,with a median value of 48 hours (range 20 minutes 18 days). Sixty seven percent of all the intervals were of 48 6 hours, 12% being shorter than 36 hours and 7% longer than 60 hours. Eighty-seven travelers (76%) took their dose faithfully on each alternate day (see Table 1),and 88% of their dose intervals were of 48 6 hours with none over 60 or under 36 hours. Although gender (female), a short trip (< 4 weeks), a hotel stay (as opposed to trekking), and the start of vaccine on the same day as the entry in the study, were factors for a better compliance, none reached statistical significance (data not shown). Receiving written information as well as oral information had a marginal but not significant impact on compliance (39/55 (71%) vs. 39/60 (65%), p =.5). Compliance in Storage and Effect on the Viability of the Vaccine All travelers said they had kept the vaccine in the refrigerator. The median time the capsules spent out of refrigerator, due to transport was 90 minutes according to the questionnaire (range 15 minutes to 65 hours). However, 50 tags ( 42%) showed exposure to temperature higher than 10 C for more than 24 hours. No vaccine was stored at temperature greater than 30 C. Table 1 Comparative Evaluation of Compliance Criterion 1:Taking Criterion 2: On Criterion 3: > 1 Hour All 3 Capsules (%) Alternate Days (%) Before Meal (%) * Overall (%) Pill count 100% na na n 115/115 MEMS 98% 76% 61% 53% n 113/115 87/115 48/79 42/79 Questionnaire 100% 89% 72% 68% n 107/107 95/107 67/93 59/87 p value Other studies Reference 11 98% 91% 99% 82% Reference 14 92% 94% 78% 70% Reference 15 99% 90% 95% >90%> n = number of subjects; na = not available. *and more than 2 hours after a meal. including keeping the vaccine under refrigeration (all travelers were compliant to this criterion). on 4 doses, by questionnaire only. Analysis of data only when the dates for taking the capsules given in the questionnaire and the MEMS where the same.
4 136 Journal of Travel Medicine, Volume 7, Number 3 Figure 1 Distribution of dose intervals assessed by electronic monitoring. Most intervals (67%) were of 48 6 hours which indicate alternate day schedule as prescribed. In 19% of cases, the interval was either longer or shorter than hours. The number of colonies grown ranged from (median ) for the capsules kept at a temperature higher than 10 C for more than 24 hours (n = 44),compared to (median ) (p =.83) for the capsules kept at lower temperatures (n = 39). The control capsules kept strictly between 2 and 8 C showed a growth between 1.5 and (median ). Discussion The results of the present study demonstrate that although all patients apparently took their 3 capsules, the overall compliance with all recommendations is rather low at 53 %. Our observation also demonstrates that electronic monitoring of compliance provides more reliable information on compliance, as it allows precise analysis of the date and timing of each drug intake. Several studies have recently evaluated patient compliance in the use of the typhoid vaccine. A comparison between our results and other studies is presented in Table 1. When assessed by a questionnaire, the overall compliance measured in our study was similar (68%) to the results described by Rahman (70%), 14 but clearly lower than the compliance reported in two other recent studies (82%, 11 >90% 15 ). The compliance in taking the 3 capsules was very good. Yet, the proportion of travelers committing compliance errors regarding the interval with meals is higher than in other studies, especially when assessed by MEMS which gives real time data. This can be partially attributed to the extra condition of taking the capsules at distance from a meal (either before or after the meal) which we required. The intervals with meals could have a theoretical influence on the vaccine efficacy if the presentation of the antigenic component of the vaccine is modified by the meals. There are no data about the effect of meals on the efficacy of the Ty21a typhoid vaccine, as all the studies have been done with the capsules or liquid formulation taken at a distance of a meal. The alternate day schedule was dutifully followed in 76% of cases and even better, 88% of their intervals were of 48 hours 6 hours,as assessed by the MEMS method. In our study, 12% of travelers had a prolonged interval between doses and 6% a shortened one. So far, no similar data are available in the literature, because few methods except electronic monitors can provide this kind of information. Little is known on the effect of the interval between the 3 doses and the efficacy of the vaccine. In a study in Chile, 3 doses taken with a 21 day interval were found to be less efficacious than doses given on alternate days, 8 but in another study protection was not affected when the 3 doses were given at weekly intervals. 24 All travelers kept the vaccine in the refrigerator (criterion 4) and although refrigeration was insufficient for 50 lots of vaccine, presumably because of poor capacity of the storage places,the viability of the capsule content was not affected by the temperature which never exceeded 30 C. Vaccine potency has been shown to be maintained even when stored at ambient temperatures for up to 7 days. 15 In 17 cases the dates indicated for ingestion on the questionnaire showed the correct interval but did not match the dates as registered by the MEMS. Apparently the travelers knew what they were expected to do, but didn t do it. In a previous study, 25 adding written information to one to one counseling did not improve compliance more than counseling alone, but this may not necessarily be the case for short-term treatments. 26 We describe a slightly better compliance of the group of travelers having received written information, but the groups are too small to show a significant difference. Measuring compliance is a difficult process as any method to measure it will introduce de ipso facto a general process reminder and improve compliance. Therefore any compliance study is likely to overestimate the compliance. In our study, the process reminder phenomenon would be similar in all groups, and the low compliance we found, would be even lower in reality. Questionnaire assessment relying on memory constantly overestimates compliance whereas electronic monitors, give the exact opening time and intervals between the taking of the capsules and are more accurate. Still, exact timing of the opening of the bottle is no proof for ingestion, and only direct observation, if feasible, would give true compliance. In conclusion, the majority of travelers take three capsules on alternate days, but many do not respect the other recommendations. Even when they know what to do, as shown by their answers in the questionnaire, they don t do it. The problem is therefore as much a
5 Stubi et al., Compliance to Oral Ty21a Vaccine 137 question of knowledge as a question of motivation. It is essential that the travelers understand the explanations and the purpose of the vaccination. The major strategies for improving adherence to treatment are to inform patients about illness and medication, to develop communication between health professionals and patients, to simplify treatment, to help the patient find convenient ways to follow the prescribed dosing regimen, and to make the patient take an active part in the treatment References 1. Swiss Federal Office of Public Health. Fièvre typhoide et paratyphoide en Suisse Bulletin de l Office Fédéral de la Santé Publique 1993; 46: Swiss Federal Office of Public Health, ed. Maladies infectieuses en Suisse Bern, Switzerland: Office Fédéral de la Santé Publique, 1999:5. 3. Reid D, Keystone JS. Health risks aboard : general considerations. In : Dupont HL, Steffen R, eds. Textbook of Travel Medicine and Health. Hamilton, Ontario : B.C. Decker Inc., 1997:5. 4. Acharya IL,Lowe MU,Thapa R,et al.prevention of typhoid fever in Nepal with Vi capsular polysaccharide of Salmonella typhi.n Engl J Med 1987; 317: Klugman KP, Gilbertson IT, Koornnof HS, et al. Protective activity of Vi capsular polysaccharide vaccine against typhoid fever. Lancet 1987; 2: Wahdan MH,Serie C,Cerisier Y,et al.a controlled field trial of live Salmonella typhi strain Ty21A oral vaccine against typhoid: three year results. J Infect Dis 1982; 145: Levine MM, Ferreccio C, Black RE, et al. Progress in vaccines against typhoid fever. Rev Infect Dis 1989; 11(3): S552 S Levine MM, Ferreccio C, Black RE, Germanier R. Largescale field trial of Ty21a live oral typhoid vaccine in entericcoated capsule formulation. Lancet 1987; 1(8541): Engels EA, Falagas ME, Lau J, Bennish ML. Typhoid fever vaccines: a meta-analysis of studies on efficacy and toxicity. BMJ 1998; 316: Hirschel B, Wüthrich R, Somaini B, Steffen R. Inefficacy of the commercial live oral Ty21A vaccine in the prevention of typhoid fever. Eur J Clin Microbiol 1985; June: Kaplan DT, Hill DR. Compliance with live, oral Ty21A typhoid vaccine. JAMA 1992; 267: Wolfe MS. Precautions with oral live typhoid (Ty21A) vaccine. Lancet 1990; 336: Cramer JA. Overview of methods to measure and enhance patient compliance. In: Cramer JA, Spilker B, eds. Patient compliance in medical practice and clinical trials. New York: Raven Press, 1991: Rahman S,Barr W,Hilton E.Use of oral typhoid vaccine strain Ty21A in a New York State travel immunization facility. Am J Trop Med Hyg 1993; 48: Cryz SJ.Patient compliance in the use of Vivotif Berna vaccine, typhoid vaccine, live oral Ty21A. J Travel Med 1998; 5: Sackett DL, Haynes RB, et al. Helping patients follow the treatments you prescribe. In: Clinical epidemiology: a basic science for clinical medecine. 2nd Ed. Boston: Little Brown and Co, 1991: Kruse W, Weber E. Dynamics of drug regimen complianceits assessement by microprocessor-based monitoring. Eur J Clin Pharmacol 1990; 38: Cramer JA. Microelectronic systems for monitoring and enhancing patient compliance with medication regimens. Drugs 1995; 49(3): Matsuyama JR, Mason BJ, Jue SG. Pharmacists interventions using an electronic medication-event monitoring device s adherence data versus pill counts. Ann Pharmacother 1993; 27: Cramer JA,Mattson RH,Prevey ML,et al.how often is medication taken as prescribed? A novel assessment technique. JAMA 1989; 261(22): Pular T, Kumar S, Tindall H, Feely M. Time to stop counting the tablets. Clin Pharmacol Ther 1989; 46: Fallab Stubi C-L, Zellweger JP, Sauty A, et al. Electronic monitoring of adherence to treatment in the preventive chemotherapy of tuberculosis. Int J Tuberc Lung Dis 1998; 2(7): McKenney JM, Munroe WP, Wright JT. Impact of an electronic medication compliance aid on long-term blood pressure control. J Clin Pharmacol 1992; 32: Simanjuntak CH, Paleologo FP, Punjabi NH, et al. Oral immunization against tyhpoid fever in Indonesia with Ty 21A vaccine. Lancet 1991; 338: Mullen PD, Green LW, Perstinger GS. Clinical trials of patient education for chronic conditions : a comparative metaanalysis of intervention types. Preventive Medecine 1985; 14: Haynes RB, McKibbon KA, Kanani R. Systematic review of randomised trials of interventions to assist patients to follow prescriptions for medications. Lancet 1996; 348: Rogers HPG, Bullman WR. Prescription medicine compliance : a review of the baseline of knowledge-a report of the national council on patient information and education. J Pharmacoepidemiol 1995; 3(2): Roter DL, Hall JA, Merisca R, et al. Effectivness of intervention to improve patient compliance, a meta-analysis. Medical Care 1998; 36(8):
Vivotif Package Insert USA Updated January 2015 Change in Ownership
Vivotif Typhoid Vaccine Live Oral Ty21a Description Vivotif (Typhoid Vaccine Live Oral Ty21a) is a live attenuated vaccine for oral administration only. The vaccine contains the attenuated strain Salmonella
More informationImmunization Dialogue
Immunization Dialogue Typhoid Vaccine Dr. T. Jacob John, Professor and Head, Department of Microbiology and Virology, Christian Medical College Hospital, Vellore, Tamil Nadu 632 004 answers important questions
More informationRESEARCH NOTE A STEP-WISE APPROACH TO FIND A VALID AND FEASIBLE METHOD TO DETECT NON-ADHERENCE TO TUBERCULOSIS DRUGS
RESEARCH NOTE A STEP-WISE APPROACH TO FIND A VALID AND FEASIBLE METHOD TO DETECT NON-ADHERENCE TO TUBERCULOSIS DRUGS R Ruslami 1, R van Crevel 2, E van de Berge 2, B Alisjahbana 3 and RE Aarnoutse 4 1
More informationOST. Gain a healthy respect for the risks of typhoid, before you. The only oral vaccine for protection against typhoid fever 1,2
Gain a healthy respect for the risks of typhoid, before you ET OST (Typhoid Vaccine Live Oral Attenuated Ty21a) 1 Typhoid fever affects about 21.5 million people each year in the developing world 3 Are
More informationPATIENT GROUP DIRECTION. Oral (live attenuated) Typhoid Vaccine (Ty21a) (Vivotif )
PATIENT GROUP DIRECTION Administration of: Oral (live attenuated) Typhoid Vaccine (Ty21a) (Vivotif ) By: Practice Nurses In: General Practice It is the responsibility of the professional working under
More informationPatient Group Direction For the supply and administration of
Patient Group Direction For the supply and administration of Vi Capsular Polysaccharide Typhoid Vaccine(Ty2) Brands TYPHERIX Vaccine TYPHIM Vi Vaccine To adults and/or children over 2 years of age Or Oral
More informationLive oral vaccine approaches to typhoid and paratyphoid vaccines
Live oral vaccine approaches to typhoid and paratyphoid vaccines Myron M. (Mike) Levine, M.D., D.T.P.H. Center for Vaccine Development. University of Maryland School of Medicine, Baltimore, MD, USA 8 th
More informationSUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT 2 QUALITATIVE AND QUANTITATIVE COMPOSITION
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Vivotif 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each capsule contains not less than 2x109 viable cells of Salmonella enterica serovar
More informationHEPATYRIX (Combined inactivated hepatitis A and Vi polysaccharide typhoid vaccine) CONSUMER MEDICINE INFORMATION LEAFLET
HEPATYRIX (Combined inactivated hepatitis A and Vi polysaccharide typhoid vaccine) CONSUMER MEDICINE INFORMATION LEAFLET WHAT IS IN THIS LEAFLET This leaflet answers some of the common questions about
More informationIndustry Perspective on Formulation and Packaging Considerations
Industry Perspective on Formulation and Packaging Considerations Ron Ogilvie (Pfizer) EFPIA February 2012 1 Industry Perspective on Formulation and Packaging Considerations Provide an overview of formulation
More informationTYPHIM Vi. Purified polysaccharide capsule of Salmonella typhi (Ty 2 strain) Consumer Medicine Information
TYPHIM Vi Purified polysaccharide capsule of Salmonella typhi (Ty 2 strain) What is in the leaflet Consumer Medicine Information This leaflet answers some common questions about TYPHIM Vi. It does not
More informationHepatitis A is a small, unenveloped, symmetrical RNA virus within the genus Hepatovirus, a member of the Picornavirus family.
Hepatitis A Introduction Hepatitis A is a small, unenveloped, symmetrical RNA virus within the genus Hepatovirus, a member of the Picornavirus family. Epidemiology (Data from the Travel Health Surveillance
More informationEnteric (typhoid or paratyphoid) fever is a systemic infection
46 REVIEW Rethinking Typhoid Fever Vaccines: Implications for Travelers and People Living in Highly Endemic Areas Jennifer A. Whitaker, MD, Carlos Franco-Paredes, MD, MPH, Carlos del Rio, MD, and Srilatha
More informationPRODUCT MONOGRAPH TYPHERIX. Salmonella typhi Vi Capsular Polysaccharide Vaccine. Liquid for injection. Active Immunizing Agent
PRODUCT MONOGRAPH TYPHERIX Salmonella typhi Vi Capsular Polysaccharide Vaccine Liquid for injection Active Immunizing Agent GlaxoSmithKline Inc. Date of Revision: 7333 Mississauga Road Mississauga, Ontario
More informationTravel. Program Management. Schedule
Program Management 69_4 YF (yellow fever) vaccine should be offered to all travellers to and from at-risk areas, unless they belong to the group of individuals for whom YF vaccination is contraindicated.
More informationTYPHIM Vi, Solution for injection
PACKAGE LEAFLET: INFORMATION FOR THE USER TYPHIM Vi, Solution for injection Purified Vi Capsular Polysaccharide of Salmonella typhi (Ty 2 Strain). Read all of this leaflet carefully before you are vaccinated
More informationHow to talk about typhoid: menu of messages
How to talk about typhoid: menu of messages PATH/Rocky Prajapati The more we talk about typhoid, the better we ll be able to prioritize it. These messages were developed for use by anyone interested in
More informationBP.06). 1.8% 11.7% ( P
AJH 2000;13:184 190 Electronic Pill-Boxes in the Evaluation of Antihypertensive Treatment Compliance: Comparison of Once Daily Versus Twice Daily Regimen Michel Andrejak, Nathalie Genes, Laurent Vaur,
More informationhttps://www.travax.com/travinfo/showarticlesummary.aspx?docid=typhoid
Page 1 of 5 Traveler Information TYPHOID GENERAL INFORMATION Introduction Typhoid fever and paratyphoid fever are bacterial infections of the intestinal tract. Typhoid is caused by Salmonella typhi and
More information(Data from the Travel Health Surveillance Section of the Health Protection Agency Communicable Disease Surveillance Centre)
Travellers Diarrhoea Introduction Travellers diarrhoea (TD) is a syndrome that commonly affects travellers caused by one of several different organisms, the most common being enterotoxigenic Escherichia
More informationTYPHERIX PRODUCT INFORMATION (Salmonella typhi Vi polysaccharide)
TYPHERIX PRODUCT INFORMATION (Salmonella typhi Vi polysaccharide) DESCRIPTION TYPHERIX is a colourless, sterile liquid containing the cell surface Vi polysaccharide extracted from Salmonella typhi Ty2
More informationTyphoid and paratyphoid fever in travellers
Typhoid and paratyphoid fever in travellers Bradley A Connor, Eli Schwartz Enteric fever a more inclusive term for typhoid fever and paratyphoid fever is a systemic infection caused by Salmonella enterica,
More informationMicrobes at Our Doorstep: Emerging issues in infection control and travel-related infections
Microbes at Our Doorstep: Emerging issues in infection control and travel-related infections Peel November 2, 2016 Learning Objectives At the end of this session, participants will be able to: 1. Identify
More informationInternational Travel Medical Questionnaire
International Travel Medical Questionnaire Name: of Birth: Gender: M/F Last First Month/Day/Year Circle One Address: Street City, State Zip Daytime Phone: Evening Phone: Primary care physician: Emergency
More informationAN OVERVIEW: THE MANAGEMENT OF FEVER IN CHILDREN
AN OVERVIEW: THE MANAGEMENT OF FEVER IN CHILDREN INTRODUCTION Fever is a normal physiological response to illness that facilitates and accelerates recovery. Although there is no evidence that children
More informationTravel-Related Infections in Canadian Children
Travel-Related Infections in Canadian Children Maryanne Crockett MD MPH FRCPC FAAP DTM&H Depts. of Pediatrics & Child Health and Medical Microbiology University of Manitoba Objectives To discuss travel-related
More informationTRAVEL VACCINATION. Acknowledgements: Dr Conrad Moreira
TRAVEL VACCINATION Acknowledgements: Dr Conrad Moreira www.who.int www.travelvaccinationcentre.com.a www.traveldoctor.com.au WWW.TRAVELDOCTOR.COM. AU Measles Home grown measles eliminated in Australia
More informationMicrobiological aspects of Salmonella including morphology, culture characters, virulence factors, carrier state and prevention.
Dr. Waleed Eldars Microbiological aspects of Salmonella including morphology, culture characters, virulence factors, carrier state and prevention. Microbiological aspects of Brucella including morphology,
More informationHealth advice for travelers
Health advice for travelers Welcome to Thailand Every year millions of tourists set Thailand as one of their favorite destinations. The information provided here will help you come up with appropriate
More informationTyphoid Fever. Information from
Typhoid Fever Information from http://kidshealth.org/en/parents/typhoid.html# Typhoid fever is a serious and sometimes life-threatening infection that mostly affects people in developing countries, where
More informationParticipant Information Sheet Ethics Approval - UQ HREC and QUT HREC
Participant Information Sheet Ethics Approval - UQ HREC 2017000186 and QUT HREC 1700001111 Project Title: A randomised placebo controlled clinical trial investigating the role of a combination of probiotics
More informationIntroduction. Infections acquired by travellers
Introduction The number of Australians who travel overseas has increased steadily over recent years and now between 3.5 and 4.5 million exits are made annually. Although many of these trips are to countries
More informationTo describe the procedure for ordering, stocking, prescribing, administering and disposal of medicines in an occupational health setting.
Purpose and Scope 1 Definitions 1 Principles 1 Responsibilities 1 Audit Criteria 2 References 2 Revision History 3 Appendix 1. Stock List 4 Appendix 2. Standing Orders 7 Appendix 3. Procedure for Ordering
More informationOral Systemic Therapy
Oral Systemic Therapy This information does not take the place of the care and advice of your Cancer Care Team. Talk to your Cancer Care Team about your health concerns, treatment options and any questions
More informationDEDICATED SUPPORT TO HELP YOU GET STARTED AND STAY ON TRACK THROUGHOUT YOUR TREATMENT
LET US HELP YOU FIND A CLEARER PATH FORWARD. DEDICATED SUPPORT TO HELP YOU GET STARTED AND STAY ON TRACK THROUGHOUT YOUR TREATMENT PERSONALIZED SUPPORT FREE MEDICATION* $0 CO-PAY* WELCOME KIT RECYCLABLE
More informationTyphoid Vi Polysaccharide Vaccine Typhim Vi
093 90426-0 A.H.F.S. Category 80:12 Typhoid Vi Polysaccharide Vaccine Typhim Vi Page 1 of 6 Caution: Federal (USA) law prohibits dispensing without prescription. DESCRIPTION Typhim Vi, Typhoid Vi Polysaccharide
More informationDirection Number: - NECSAT 2017/004
Patient Group Direction (PGD) for the Administration of TYPHOID VACCINES (TYPHIM Vi, TYPHERIX and VIVOTIF ) by Registered Professionals to Individuals Accessing NHS Services in Cumbria and North East Sub
More informationRisk Consultation and Assessment
Risk Consultation and Assessment Please find product Prescribing Information at the end of this presentation UK/VAC/0047/16b Date of preparation: July 2016 The pre-travel risk consultation When to do it?
More informationPrequalification Team WHO PUBLIC INSPECTION REPORT Vaccine Manufacturer
20, avenue Appia CH-1211 Geneva 27 Switzerland Tel central +41 22 791 2111 Fax central +41 22 791 3111 www.who.int Part 1: General information Name of Manufacturer Prequalification Team WHO PUBLIC INSPECTION
More informationEXPANDED PROGRAM OF IMMUNIZATION (EPI) Definition Program adopted by WHO since l974, it includes child immunization & vaccination of pregnant women.
EXPANDED PROGRAM OF IMMUNIZATION (EPI) Definition Program adopted by WHO since l974, it includes child immunization & vaccination of pregnant women. Strategy A. Child immunization Egyptian immunization
More information(Typhoid Vi Capsular Polysaccharide-Tetanus Toxoid Conjugate Vaccine)
(Typhoid Vi Capsular Polysaccharide-Tetanus Toxoid Conjugate Vaccine) 9th International Conference on Typhoid and invasive NTS Disease 30 th April 3 rd May 2015 Vineeth Varanasi Before the beginning: Typhoid
More informationInterventions to Improve Follow-up of Positive Results on Fecal Blood Tests
Interventions to Improve Follow-up of Positive Results on Fecal Blood Tests Results of a systematic review, Kaiser experience, and implications for the Canton of Vaud Kevin Selby, M.D. Kevin.Selby@hospvd.ch
More informationProgress in typhoid epidemiology
Progress in typhoid epidemiology John A. Crump, MB ChB, MD, DTM&H McKinlay Professor of Global Health 10 th International Conference on Typhoid and Other Invasive Salmonelloses 4 April 2017 Overview Mode
More informationDepartment of Epidemiological Surveillance and Intervention
EPIDEMIOLOGICAL DATA FOR ΤYPHOID/PARATYPHOID FEVER IN GREECE, 2004-2016 MANDATORY NOTIFICATION SYSTEM NATIONAL REFERENCE CENTRE FOR SALMONELLA AND SHIGELLA Main points The notification rate for typhoid/paratyphoid
More informationDepartment of Epidemiological Surveillance and Intervention
EPIDEMIOLOGICAL DATA FOR ΤYPHOID/PARATYPHOID FEVER IN GREECE, 2004-2017 MANDATORY NOTIFICATION SYSTEM NATIONAL REFERENCE CENTRE FOR SALMONELLA AND SHIGELLA Main points The notification rate for typhoid/paratyphoid
More informationProgress and Challenges of Enteric Vaccines. Dr. Tajul Islam A Bari icddr,b Bangladesh
Progress and Challenges of Enteric Vaccines Dr. Tajul Islam A Bari icddr,b Bangladesh New enteric vaccines in use Cholera Rotavirus Typhoid Cholera- History During the 19th century, cholera spread across
More informationCholera Clinical Guidelines. OAHPP Rounds January 11, 2011 Vanessa G. Allen MD FRCPC Medical Microbiologist
Cholera Clinical Guidelines OAHPP Rounds January 11, 2011 Vanessa G. Allen MD FRCPC Medical Microbiologist Overview Cholera clinical guidelines Development and review process Content Reference for diagnosis,
More informationWill live oral vaccines work in children in the developing world? Martin Friede Ph.D. Initiative for Vaccine Research
Will live oral vaccines work in children in the developing world? Martin Friede Ph.D. Initiative for Vaccine Research Estimated global distribution of the 600,000 annual deaths caused by rotavirus 2 1
More informationSAY HELLO TO CLEARER SKIN. SAY HELLO TO TREMFYA.
FOR PATIENTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS SAY HELLO TO CLEARER SKIN. SAY HELLO TO TREMFYA. INDIVIDUAL RESULTS MAY VARY TREMFYA is a prescription medicine used to treat adults with moderate
More informationDevelopment, use and refinement of enterotoxigenic Escherichia coli (ETEC) controlled human infections
Development, use and refinement of enterotoxigenic Escherichia coli (ETEC) controlled human infections Chad Porter, PhD, MPH Enteric Diseases Department Naval Medical Research Center Disclaimer & Copyright
More informationDirection Number: - NECSAT 2015/004
Patient Group Direction (PGD) for the Administration of TYPHOID VACCINES (TYPHIM Vi, TYPHERIX and VIVOTIF ) by Registered Professionals to Individuals Accessing NHS Services in Cumbria and North East Sub
More informationTraveling with Inflammatory Bowel Disease. Suresh Pola MD Inflammatory Bowel Disease Center UC San Diego Health System
Traveling with Inflammatory Bowel Disease Suresh Pola MD Inflammatory Bowel Disease Center UC San Diego Health System Overview What You Need to Do Now Pre-Travel Preparation While You Are Away When You
More informationAustralian Medicinal Cannabis Pricing Analysis
Australian Medicinal Cannabis Pricing Analysis Q3 2018 cannabis access clinics » Entry level product prices fall by close to 50% over 12 months» Number of legal products available up threefold» Pharmacy
More informationHow E-connected medicine will change the value of pharmaceuticals. Overview of current initiatives on digital pill
How E-connected medicine will change the value of pharmaceuticals Overview of current initiatives on digital pill Professor Mondher Toumi Aix Marseille University ISPOR Asia Pacific 08 Agenda Burden of
More informationPan American Health Organization PAHO/ACMR 14/18 Original: English
Pan American Health Organization PAHO/ACMR 14/18 Original: English FOURTEENTH MEETING OF THE ADVISORY COMMITTEE ON MEDICAL RESEARCH W"shington, D.C. 7-10 July 1975 FIELO TRIALS WITH KILLED ORAL TYPHOID
More informationInformed Consent Flipchart. Version 1.0, 30 Jan 2018
Informed Consent Flipchart Version 1.0, 30 Jan 2018 Knowledge is Power Did you know? Across the world, young women are at high risk of getting HIV. In Africa, more than half of people living with HIV are
More informationTravel-Related Shigellosis in Quebec, Canada: An Analysis of Risk Factors
I S T M 304 ORIGINAL ARTICLE Travel-Related Shigellosis in Quebec, Canada: An Analysis of Risk Factors Stéphane Trépanier, MD, FRCPC, Yen-Giang Bui, MD, DTMH, Manon Blackburn, MD, FRCPC, François Milord,
More informationCOPYRIGHTED MATERIAL. Introduction
1 Introduction Pharmacology is the science of drugs and their effects on biological systems. A drug can be defined as a chemical that can cause a change in a biological system; the important biological
More informationImproving Medication Adherence through Collaboration between Colleges of Pharmacy and Community Pharmacies
Improving Medication Adherence through Collaboration between Colleges of Pharmacy and Community Pharmacies Megan Willson, PharmD, BCPS; Catrina Schwartz, PharmD, BS; Jennifer Robinson, PharmD Spokane,
More informationSorafenib (Nexavar ) ( sor-af-e-nib )
Sorafenib (Nexavar ) ( sor-af-e-nib ) How the drug is given: by mouth Purpose: To stop the growth of cancer cells in kidney cancer, liver cancer, and other cancers How to take the drug by mouth Take on
More informationOur Mission. To promote healthy and safe travel by providing medicines, preventive vaccines and health counseling to a diverse group of travelers
Our Mission To promote healthy and safe travel by providing medicines, preventive vaccines and health counseling to a diverse group of travelers The Travel Clinic utilizes national and international travel
More informationLooking for Evidence that Personal Hygiene Precautions Prevent Traveler s Diarrhea
SUPPLEMENT ARTICLE Looking for Evidence that Personal Hygiene Precautions Prevent Traveler s Diarrhea David R. Shlim Jackson Hole Travel and Tropical Medicine, Jackson, Wyoming In the 50 years during which
More informationLet s Talk TB A Series on Tuberculosis, A Disease That Affects Over 2 Million Indians Every Year
A Series on Tuberculosis, A Disease That Affects Over 2 Million Indians Every Year Madhukar Pai, MD, PhD Author and Series Editor Camilla Rodrigues, MD co-author Abstract Most individuals who get exposed
More informationUpdates on Typhoid Conjugate vaccine Development: IVI
Updates on Typhoid Conjugate vaccine Development: IVI Sushant Sahastrabuddhe 8 th International Conference on Typhoid Fever and Other Invasive Salmonelloses 2 nd March 2013 Outline of the presentation
More informationPatient Group Direction For the supply and administration of
Patient Group Direction For the supply and administration of COMBINED HEPATITIS A AND HEPATITIS B VACCINE TWINRIX PAEDIATRIC For Children aged 1 year to under 16 years TWINRIX ADULT For Adults and Adolescents
More informationReport to the Board. Typhoid vaccines: WHO Position paper. Weekly epidemiological record. 2008; 6: ibid
Annex B: Background and Overview of Analyses Gavi s Historical Decisions on TCV In the 2008 VIS, the Board prioritised TCVs for Gavi s portfolio along with Rubella, HPV, and JE vaccines. Although no financial
More informationZANOSAR 1g. STREPTOZOCINE Lyophilised powder for solution for injection
PACKAGE LEAFLET: INFORMATION FOR THE USER ZANOSAR 1g STREPTOZOCINE Lyophilised powder for solution for injection Read all of this leaflet carefully before you start using this medicine. Keep this leaflet.
More informationMedication, Travel and You
Medication, Travel and You Zahra demolitor Pharmacist Owner Shoppers Drug Mart, Upper Tantallon January 17, 2013 1 Outline Drug Plans & Vacation Supplies How to pack medications Days supply you can take
More informationGUIDE TO INFECTION CONTROL IN THE HOSPITAL. Carbapenem-resistant Enterobacteriaceae
GUIDE TO INFECTION CONTROL IN THE HOSPITAL CHAPTER 47: Carbapenem-resistant Enterobacteriaceae Authors E-B Kruse, MD H. Wisplinghoff, MD Chapter Editor Michelle Doll, MD, MPH) Topic Outline Key Issue Known
More informationFamily Compliance With Counseling for Children Traveling to the Tropics
171 ORIGINAL ARTICLE Family Compliance With Counseling for Children Traveling to the Tropics Stéphanie Caillet-Gossot, MD, Rémi Laporte, MD, Guilhem Noël, MD, Philippe Gautret, MD, PhD, Georges Soula,
More informationHuman Cases of Influenza A (H1N1) of Swine Origin in the United States and Abroad Updated Key Points April 29, 2008: 9:58AM
Situation Update CDC is reporting 91 human infections with this influenza A (H1N1) virus of swine origin in the United States. (An increase in 27 over the number of cases reported yesterday.) The list
More informationCRITICAL APPRAISAL OF MEDICAL LITERATURE. Samuel Iff ISPM Bern
CRITICAL APPRAISAL OF MEDICAL LITERATURE Samuel Iff ISPM Bern siff@ispm.unibe.ch Contents Study designs Asking good questions Pitfalls in clinical studies How to assess validity (RCT) Conclusion Step-by-step
More informationTyphoidal pathogens. - S. Typhi Vi-positive - S. Typhi Vi-negative. Journal of clinical microbiology, 2005,
Typhoid Typhoid is an acute infectious febrile illness with anorexia, headache, malaise and abdominal discomfort Global burden is more than 27 million 0.2 Million deaths annually verall 90% cases reported
More information(1) an oral, enteric coated capsule containing live Type 21A whole cell vaccine, 'Vivotif'; and
A cost-effectiveness analysis of typhoid fever vaccines in US military personnel Warren T A, Finder S F, Brier K L, Ries A J, Weber M P, Miller M R, Potyk R P, Reeves S, Moran E L, Tornow J J Record Status
More informationUNIVERSITY OF UTAH INTERNATIONAL TRAVEL CLINIC Phone: Fax: N Medical Dr. Salt Lake City, UT 84132
Welcome to UNIVERSITY OF UTAH INTERNATIONAL TRAVEL CLINIC Phone: 801-801-581-2898 Fax: 801-585-7315 50 N Medical Dr. Salt Lake City, UT 84132 Our goal is to help you have a safe and enjoyable experience
More informationPatient Group Direction (PGD) Number :
Notice to all staff: The Patient Group Directions (PGDs) for the Hertfordshire and South Midlands Area Team may only be used by members of the healthcare professions named on the title page, and only if
More informationAPPROVED AT REGIONAL COUNCIL September 13,201 2
Region of Peel APPROVED AT REGIONAL COUNCIL September 13,201 2 HE-6. INTERDEPARTMENTAL HE-Bl. Health in Peel: Communicable Disease, 2006-2010 Presentation by Dr. Eileen de Villa, Associate Medical Officer
More informationSTATEMENT ON INTERNATIONAL TRAVELLERS AND TYPHOID
STATEMENT ON INTERNATIONAL TRAVELLERS AND TYPHOID AN ADVISORY COMMITTEE STATEMENT (ACS) COMMITTEE TO ADVISE ON TROPICAL MEDICINE AND TRAVEL (CATMAT) PROTECTING CANADIANS FROM ILLNESS TO PROMOTE AND PROTECT
More informationSUMMARY OF PRODUCT CHARACTRISTICS
1. NAME OF THE MEDICINAL PRODUCT Typhoid (Vi Capsular Polysaccharide)-Tetanus Toxoid Conjugate Vaccine. Typbar-TCV 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Qualitative Formula per dose of 0.5 ml (Single
More informationAntimalarials in the WHO Essential Drugs List for Children Reviewer No.1
Antimalarials in the WHO Essential Drugs List for Children Reviewer No.1 Part I: Evaluation of the current list Proposed grouping from the March 2007 meeting 6.5.3 Antimalarial medicines 6.5.3.1 For curative
More informationPatient Group Direction
This Patient Group Direction (PGD) must only be used by registered health professionals who have been named and authorised by their organisation to practice under it. The most recent and in date final
More informationOral Systemic Therapy
Patient & Family Guide 2018 Oral Systemic Therapy www.nscancercare.ca Patient s Name: Type of Treatment: Cancer Doctor: Cancer Clinic: Phone Number: Emergency Department Phone Number: Who do I call if
More informationHomely Remedies Guidance for Care Homes
Homely Remedies Guidance for Care Homes What is a homely remedy? Homely or household remedy is another name for a non-prescription medicine which is used in a care home for the short term management of
More informationPDF of Trial CTRI Website URL -
Clinical Trial Details (PDF Generation Date :- Fri, 22 Feb 2019 22:24:32 GMT) CTRI Number Last Modified On 06/11/2012 Post Graduate Thesis Type of Trial Type of Study Study Design Public Title of Study
More informationPlease note: Forms with PXXXX designations can be found at All other forms can be found at
ADULT SAFETY NET (ASN) PROGRAM 2018 COMPLIANCE SITE VISIT FOLLOW-UP PLAN This document is used to track required follow-up actions at the completion of an ASN compliance site visit. When all follow-up
More informationMalaria Prophylaxis in Different Age Groups
Malaria Prophylaxis in Different Age Groups Marie-Louise Mittelholzer, Michael Wall, Robert Steflen, and Dieter Stiirchler Background: There is a perceived increased health risk in senior visitors to malaria
More informationStart your patient s drug education
PDR Network Provider Solutions: PDR + for Patients Here Start your patient s drug education So They Get Here FREE Patient Drug Education from PDR PDR+ helps you educate your patients about their prescriptions.
More informationDo Silicea products for internal application contain preservatives or substances of animal origin?
General Questions Is silicon (Si) an essential trace element? Compared with other trace elements, the outstanding significance of silicon (Si) for the health of more highly developed organisms was recognised
More informationShort consensus Short consensus 25/1/2018. Dr Ula Maniewski-ITG
Short consensus 25-1-2018 Short consensus 25/1/2018 Dr Ula Maniewski-ITG YellowFever Yellow fever map South America 2018 2014 Outbreak YF in Brazil several cases in Sao Paulo-city Yellowfever: forhowlong
More informationIntervention to improve adherence to Type 2 Diabetes mellitus subjects in rural teaching hospital
Available online at wwwscholarsresearchlibrarycom Scholars Research Library Der Pharmacia Lettre, 2016, 8 (1):361-367 (http://scholarsresearchlibrarycom/archivehtml) ISSN 0975-5071 USA CODEN: DPLEB4 Intervention
More informationا.م.د.هيفاء الحديثي. Enterobacteriaceae
ا.م.د.هيفاء الحديثي Bacteriology Genus Salmonella Enterobacteriaceae - Pathogenic for human and animals - They are gram negative rods, motile with peritrichous flagella except Gallinarum-pullorum - Ferment
More informationRisk of malaria in Travelers
Malaria Prevention & Chemoprophylaxis Risk of malaria in Travelers Watcharapong Piyaphanee MD, Board Int Med, CTH, Dip Trav Med, MFTM RCPS (Glasgow) Travel Medicine Research Unit Faculty of Tropical Medicine,
More informationPRE- TRAVEL QUESTIONNAIRE
Ph: 03 313 7877 Fax: 03 313 7861 Email: admin@medicalcorner.co.nz 237 High Street, Rangiora 7400 PRE- TRAVEL QUESTIONNAIRE Please add as much detail to this form as possible as this will ensure that the
More informationYour Healing Arthritis Supplement Kit
Your Healing Arthritis Supplement Kit Instructions for the full 90-Day Arthritis Program Congrats! You will be receiving Dr. Blum s most highly recommended anti-arthritis supplements in this kit. Here
More informationMs. S, age 53, has bipolar disorder,
How you can simplify your patient s medication regimen to enhance adherence Colleen P. Hall, PharmD, BCPP Vicki L. Ellingrod, PharmD, FCCP Department Editor is produced in partnership with the College
More informationVirginia Beach Department of Emergency Medical Services. CAAS # Index # Administration VACCINATION POLICY
Virginia Beach Department of Emergency Medical Services CAAS # 106.01.01 Index # Administration VACCINATION POLICY PURPOSE: This policy is designed to provide guidance in operating a program for the administration
More informationAfter i.v injection 45% of the amount of desmopressin is found in the urine within 24 hours.
MINIRIN Tablets 0.1 and 0.2 mg Declaration Tablets 0.1 mg. Each tablet contains desmopressin acetate 0.1 mg and excipients q.s Tablets 0.2 mg. Each tablet contains desmopressin acetate 0.2 mg and excipients
More informationAppendix B Patient Stories
Sharing patient stories is a powerful way to illustrate key messages about medication safety. Use your own stories, ask for your audience to share stories, and/or choose from those described below. Share
More informationMultidrug-resistant Tuberculosis - World, Europe, Switzerland
Multidrug-resistant Tuberculosis - World, Europe, Switzerland Magglingen March 23, 2017 peter.helbling@bag.admin.ch Topics Definitions Epidemiology of TB and MDR-TB worldwide Treatment outcome results
More information